10.2 Drug Interactions, CYP450, P-gp & Transporters

Drug Interactions, CYP450, P-gp & Transporters

Executive Summary: Drug interactions represent a major preventable cause of clinical morbidity, therapeutic failure, and hospital admissions in outpatient pharmacotherapy. Pharmacokinetic drug-drug interactions alter substrate absorption, distribution, metabolism, or elimination via the Cytochrome P450 (CYP450) enzymatic superfamily and membrane transport proteins, including P-glycoprotein (P-gp / ABCB1) and Organic Anion Transporting Polypeptides (OATPs / SLCO1B1). Concurrently, additive or antagonistic pharmacodynamic interactions—such as the renal 'Triple Whammy', additive QTc prolongation, and multi-agent serotonergic toxicity—can produce catastrophic adverse outcomes even in the absence of altered serum concentrations. The Board Certified Ambulatory Care Pharmacist (BCACP) must master interaction kinetics, recognize high-risk drug pairs, interpret pharmacogenomic phenotypes, and execute preemptive dose adjustments.

1. CYP450 Enzyme Systems: Kinetics, Inhibitors, Inducers & Substrates

Phase I hepatic metabolism is mediated by the microsomal Cytochrome P450 mixed-function oxidase system located on the smooth endoplasmic reticulum of hepatocytes and enterocytes.

Enzyme Inhibition vs. Enzyme Induction Kinetics

• CYP450 Enzyme Inhibition: Occurs rapidly—often within hours to 24–48 hours of starting the inhibitor. The inhibitor binds directly to the enzyme (competitive, non-competitive, or mechanism-based suicide inhibition), blocking substrate clearance. Substrate serum concentrations ($AUC$, $C_{max}$) rise rapidly, precipitating acute toxicity.
• CYP450 Enzyme Induction: Occurs gradually. The inducer binds nuclear receptors (e.g., Pregnane X Receptor [PXR], Constitutive Androstane Receptor [CAR]), stimulating de novo enzyme protein synthesis. Maximal induction takes 7 to 14 days to develop. When the inducer is discontinued, the induction effect persists for 1 to 3 weeks while excess enzyme molecules degrade. Substrate serum levels decline, precipitating therapeutic failure (e.g., breakthrough seizures, graft rejection, pregnancy).

┌────────────────────────────────────────────────────────────────────────┐
│                     CYP450 ISOENZYME REFERENCE MATRIX                  │
├─────────┬──────────────────────────┬───────────────────────────────────┤
│ ENZYME  │ POTENT INHIBITORS        │ POTENT INDUCERS                   │
├─────────┼──────────────────────────┼───────────────────────────────────┤
│ CYP3A4  │ • Clarithromycin, Erythro│ • Rifampin, Rifabutin             │
│ (50% of │ • Ketoconazole, Itracon. │ • Carbamazepine, Phenytoin        │
│ drugs)  │ • Posaconazole, Voricon. │ • Phenobarbital, Primidone        │
│         │ • Ritonavir, Cobicistat  │ • St. John's Wort                 │
│         │ • Grapefruit juice       │ • Enzalutamide                    │
├─────────┼──────────────────────────┼───────────────────────────────────┤
│ CYP2D6  │ • Fluoxetine, Paroxetine │ • NON-INDUCIBLE ENZYME            │
│ (20% of │ • Bupropion              │   (Gene duplication causes UM     │
│ drugs)  │ • Quinidine, Terbinafine │    phenotype, not xenobiotics)    │
├─────────┼──────────────────────────┼───────────────────────────────────┤
│ CYP2C9  │ • Amiodarone, Fluconazole│ • Rifampin                        │
│ (Warfarin│ • TMP-SMX (Bactrim)      │ • Carbamazepine                   │
│ active) │ • Metronidazole          │ • St. John's Wort                 │
├─────────┼──────────────────────────┼───────────────────────────────────┤
│ CYP2C19 │ • Omeprazole, Esomepraz. │ • Rifampin                        │
│ (Plavix │ • Fluconazole, Fluvoxam. │                                   │
│ bioact.)│ • Ticlopidine            │                                   │
├─────────┼──────────────────────────┼───────────────────────────────────┤
│ CYP1A2  │ • Ciprofloxacin          │ • Tobacco smoking (PAHs)          │
│         │ • Fluvoxamine            │ • Charbroiled meat, Carbamazepine │
└─────────┴──────────────────────────┴───────────────────────────────────┘

Clinical Nuances by Specific CYP450 Isoenzymes

1. CYP3A4 (The Workhorse Isoenzyme)

CYP3A4 is the most abundant CYP enzyme in the liver and intestinal mucosa, metabolizing >50% of all marketed drugs.

• Critical Substrates: Simvastatin, Lovastatin, Atorvastatin; Direct Oral Anticoagulants (Apixaban, Rivaroxaban); Calcineurin inhibitors (Tacrolimus, Cyclosporine); Ticagrelor; Phosphodiesterase-5 inhibitors (Sildenafil, Tadalafil); Calcium channel blockers (Amlodipine, Diltiazem, Verapamil); Fentanyl, Oxycodone, Methadone.
• Strong Inhibitor Co-Administration:
  • Co-administering Simvastatin or Lovastatin with clarithromycin, ketoconazole, or protease inhibitors is contraindicated due to massive (up to 10- to 20-fold) increases in statin AUC, triggering severe rhabdomyolysis and renal failure.
  • Co-administering Apixaban or Rivaroxaban with strong dual CYP3A4/P-gp inhibitors (e.g., ketoconazole, itraconazole, ritonavir) requires significant dose reduction or complete avoidance.
• Strong Inducer Co-Administration:
  • Rifampin, Carbamazepine, Phenytoin, or St. John's Wort co-administered with DOACs, oral contraceptives, tacrolimus, or antiretrovirals drops substrate serum levels by 50% to 90%, causing catastrophic clinical failures (fatal stroke, organ transplant rejection, unplanned pregnancy).

2. CYP2D6 (Polymorphisms & Prodrug Bioactivation)

CYP2D6 exhibits significant genetic polymorphism with four distinct metabolizer phenotypes: Poor Metabolizers (PMs), Intermediate Metabolizers (IMs), Extensive (Normal) Metabolizers (NMs), and Ultra-Rapid Metabolizers (UMs).

• Prodrug Bioactivation Requirements:
  • Codeine $\rightarrow$ Morphine (via CYP2D6 O-demethylation).
  • Tramadol $\rightarrow$ O-desmethyltramadol (M1 metabolite) (300-fold higher mu-receptor affinity than parent tramadol).
  • Tamoxifen $\rightarrow$ Endoxifen (active anti-estrogen metabolite in breast cancer).
• Phenotypic Consequences:
  • Ultra-Rapid Metabolizers (UMs): Rapidly convert codeine or tramadol into dangerously high circulating levels of active morphine or M1. FDA Boxed Warning: Fatal respiratory depression has occurred in pediatric patients (especially post-tonsillectomy/adenoidectomy) and nursing infants of mothers who are CYP2D6 UMs. Codeine and tramadol are contraindicated in children $<12$ years and nursing mothers.
  • Poor Metabolizers (PMs): Inability to bioactivate codeine, tramadol, or tamoxifen. PMs experience complete lack of analgesia from codeine/tramadol and increased risk of breast cancer recurrence on tamoxifen.
• Potent CYP2D6 Inhibitors (Fluoxetine, Paroxetine, Bupropion): Phenocopy poor metabolizers. When combined with metoprolol or carvedilol, CYP2D6 inhibition increases beta-blocker plasma levels 3- to 5-fold, inducing profound bradycardia, heart block, and hypotension.

3. CYP2C9 (Warfarin S-Enantiomer Clearance)

• Warfarin is a racemic mixture of R- and S-enantiomers. The S-enantiomer is 3 to 5 times more potent than the R-enantiomer at inhibiting Vitamin K Epoxide Reductase (VKORC1). S-warfarin is cleared almost exclusively by CYP2C9.
• Amiodarone Interaction: Amiodarone and its active metabolite DEA potently inhibit CYP2C9 (as well as CYP3A4, CYP2C19, and P-gp). When amiodarone is initiated in a patient taking warfarin, the warfarin dose must be empirically reduced by 30% to 50% to prevent severe INR elevation and catastrophic intracranial/gastrointestinal hemorrhage.
• Bactrim (TMP-SMX) & Metronidazole: Potent inhibitors of CYP2C9. Co-administration with warfarin routinely doubles or triples the INR within 3 to 5 days, requiring preemptive warfarin dose reductions of 25% to 50% and frequent INR monitoring.

4. CYP2C19 (Clopidogrel Bioactivation & PPI Interaction)

• Clopidogrel (Plavix) is an inactive prodrug requiring a two-step hepatic bioactivation process. CYP2C19 is the primary enzyme responsible for generating the active thiol metabolite that irreversibly inhibits platelet $\text{P2Y}_{12}$ ADP receptors.
• **CYP2C19 Loss-of-Function (2, 3 alleles): Patients who are CYP2C19 Poor Metabolizers produce significantly lower concentrations of the active thiol metabolite, resulting in diminished antiplatelet response and significantly higher rates of stent thrombosis, myocardial infarction, and death following percutaneous coronary intervention (PCI). FDA Boxed Warning: Consider alternative $\text{P2Y}_{12}$ inhibitors (Prasugrel or Ticagrelor) in known CYP2C19 PMs.
• The Omeprazole Interaction: Omeprazole and Esomeprazole are competitive inhibitors of CYP2C19. Co-administration diminishes clopidogrel bioactivation. If a PPI is indicated in a patient receiving clopidogrel, Pantoprazole is preferred due to its weak CYP2C19 inhibitory profile.

2. Drug Transporters: P-glycoprotein (P-gp) & OATPs

Membrane transporters dictate the influx and efflux of drugs across biological membranes in the intestine, liver, kidneys, and blood-brain barrier.

1. P-glycoprotein (P-gp / MDR1 / ABCB1)

P-gp is an ATP-dependent efflux pump located on the apical membrane of:

• Enterocytes: Pumps absorbed drug back into the intestinal lumen (limits bioavailability).
• Hepatocytes: Pumps drug into the biliary canaliculi (facilitates biliary excretion).
• Renal Proximal Tubules: Pumps drug into the tubular lumen (facilitates urinary excretion).
• Brain Capillary Endothelium: Pumps drug back into systemic circulation (protects CNS).

                                P-GLYCOPROTEIN (P-gp) INTERACTION DYNAMICS
                                
    [ P-gp INHIBITION ]                                      [ P-gp INDUCTION ]
    (Amiodarone, Verapamil, Quinidine,                       (Rifampin, St. John's Wort,
     Clarithromycin, Itraconazole)                            Carbamazepine)
                 │                                                         │
                 ▼                                                         ▼
    • ↓ Intestinal Efflux (↑ Bioavailability)                • ↑ Intestinal Efflux (↓ Bioavailability)
    • ↓ Renal Tubular Excretion                              • ↑ Renal Tubular Secretion
                 │                                                         │
                 ▼                                                         ▼
    SUBSTRATE CONCENTRATIONS SURGE                           SUBSTRATE CONCENTRATIONS PLUMMET
    • Digoxin levels double (arrhythmias)                    • DOAC levels drop (stroke risk)
    • DOAC levels surge (hemorrhage)                         • Tacrolimus levels drop (rejection)
    ★ REDUCE DIGOXIN DOSE BY 50%!                            ★ AVOID CO-ADMINISTRATION!

High-Yield P-gp Interactions in Outpatient Care:

• Digoxin + P-gp Inhibitors (Amiodarone, Verapamil, Diltiazem, Quinidine): P-gp inhibition decreases digoxin renal clearance and increases intestinal absorption, doubling serum digoxin levels. Clinical Rule: Empirically reduce the digoxin dose by 50% whenever initiating amiodarone, verapamil, or quinidine, and monitor serum levels closely (target 0.5–0.9 ng/mL for heart failure).
• Dabigatran (Pradaxa) + P-gp Inhibitors: Dabigatran etexilate is a selective P-gp substrate. In patients with moderate renal impairment (CrCl 30–50 mL/min), co-administration with strong P-gp inhibitors (dronedarone, systemic ketoconazole) requires reducing dabigatran to 75 mg PO BID. In patients with CrCl <30 mL/min, concomitant use is contraindicated.
• Colchicine + P-gp / Strong CYP3A4 Inhibitors: Colchicine is a dual P-gp and CYP3A4 substrate. Combining colchicine with clarithromycin, ketoconazole, or cyclosporine leads to life-threatening fatal colchicine toxicity (rhabdomyolysis, bone marrow suppression, multi-organ failure). Concomitant use in renal or hepatic impairment is absolutely contraindicated.

2. Organic Anion Transporting Polypeptides (OATPs / SLCO1B1)

OATPs (specifically OATP1B1 and OATP1B3) are sinusoidal influx transporters on hepatocytes that extract endogenous compounds (bilirubin) and medications from portal blood into the liver for metabolism and biliary clearance.

The Gemfibrozil + Statin Interaction (Severe Rhabdomyolysis)

• Mechanism: Gemfibrozil (and its glucuronide metabolite) is a potent, irreversible inhibitor of OATP1B1 and also inhibits CYP2C8-mediated glucuronidation.
• Clinical Consequence: Blocking OATP1B1 prevents statins (Simvastatin, Lovastatin, Pravastatin, Atorvastatin, Rosuvastatin) from entering hepatocytes. Statin systemic blood concentrations surge dramatically (simvastatin acid AUC increases up to 3- to 6-fold), triggering severe statin-induced myopathy, rhabdomyolysis, myoglobinuric acute renal failure, and death.
• Clinical Practice Rule: Gemfibrozil is CONTRAINDICATED with Simvastatin, Lovastatin, and Pravastatin, and should be avoided with all statins. If a fibrate is required in a patient on a statin (for severe hypertriglyceridemia $\ge 500\text{ mg/dL}$), Fenofibrate is the preferred agent because it does not significantly inhibit OATP1B1 or statin glucuronidation.
• Cyclosporine + Statins: Cyclosporine strongly inhibits OATP1B1 and CYP3A4. Rosuvastatin AUC increases 7-fold; max rosuvastatin dose with cyclosporine is 5 mg daily; atorvastatin max dose is 10 mg daily.

3. High-Risk Pharmacodynamic Drug Interactions

Pharmacodynamic interactions occur when two or more drugs produce additive, synergistic, or antagonistic clinical effects without altering each other's plasma concentrations.

1. The Renal 'Triple Whammy' (Acute Kidney Injury)

The combination of an ACE Inhibitor or ARB + NSAID + Diuretic (Loop or Thiazide) produces a catastrophic hemodynamic collapse within the renal glomerulus.

                                  THE RENAL "TRIPLE WHAMMY" CASCADE
                                  
     [ 1. DIURETIC ]                       [ 2. NSAID ]                    [ 3. ACEi / ARB ]
     • Induces intravascular plasma       • Blocks COX-1/COX-2            • Blocks Angiotensin II
       volume contraction                   prostaglandins (PGE2, PGI2)     mediated vasoconstriction
     • ↓ Renal perfusion pressure         • Prevents compensatory         • Dilates EFFERENT
       to the afferent arteriole            vasodilation                    arteriole
                 │                        • CONSTRICTS AFFERENT ARTERIOLE             │
                 │                                     │                              │
                 ▼                                     ▼                              ▼
     [ Decreased Inflow Pressure ]       [ Impaired Blood Inflow ]     [ Uninhibited Blood Outflow ]
                 │                                     │                              │
                 └─────────────────────────────────────┼──────────────────────────────┘
                                                       │
                                                       ▼
                               [ CATASTROPHIC PLUMMET IN INTRAGLOMERULAR ]
                               [        HYDROSTATIC PRESSURE & GFR       ]
                                                       │
                                                       ▼
                               [ ACUTE OLIGURIC RENAL FAILURE & SEVERE HYPERKALEMIA ]

• Clinical Rule: In patients taking an ACEi/ARB and a diuretic, avoid oral NSAIDs entirely. Utilize topical NSAIDs (diclofenac gel), acetaminophen, or non-pharmacologic interventions for musculoskeletal pain.

2. Additive QTc Prolongation & Torsades de Pointes (TdP)

Co-prescribing multiple medications that block cardiac potassium rectifier channels ($I_{Kr}$) delays ventricular repolarization, prolonging the corrected QT interval (QTc) and predisposing to fatal Torsades de Pointes ventricular tachycardia.

• Major Risk Factors: Baseline $\text{QTc} > 500\text{ ms}$ (or $\Delta \text{QTc} > 60\text{ ms}$ from baseline), female sex, age $>65$, hypokalemia ($K^+ < 4.0\text{ mEq/L}$), hypomagnesemia ($Mg^{2+} < 2.0\text{ mg/dL}$), baseline bradycardia, and underlying heart failure.
• High-Risk QTc-Prolonging Classes & Combinations:
  • Antiarrhythmics: Class IA (Quinidine, Procainamide), Class III (Amiodarone, Sotalol, Dofetilide, Dronedarone).
  • Psychotropics: Antipsychotics (Haloperidol, Chlorpromazine, Ziprasidone, Quetiapine); Antidepressants (Citalopram [max dose 40 mg daily in adults; max 20 mg daily in age >60 or hepatic impairment], Escitalopram [max 10 mg in age >60], TCAs); Methadone.
  • Antimicrobials: Fluoroquinolones (Moxifloxacin > Levofloxacin > Ciprofloxacin); Macrolides (Erythromycin > Clarithromycin > Azithromycin); Azole antifungals.
  • Antiemetics: Ondansetron (max single IV dose 16 mg), Droperidol.

3. Multi-Agent Serotonin Syndrome

Excessive intrasynaptic serotonin ($5\text{-HT}$) stimulation from concurrent serotonergic agents triggers life-threatening neuromuscular and autonomic toxicity.

• High-Risk Culprit Agents: SSRIs, SNRIs, TCAs, MAOIs (Phenelzine, Tranylcypromine, Selegiline), Linezolid (reversible non-selective MAOI), IV Methylene Blue (potent MAOI), Triptans, Tramadol, Meperidine, Dextromethorphan, and St. John's Wort.
• Hunter Serotonin Toxicity Criteria: Diagnosed when a patient receives a serotonergic agent and exhibits any of the following: (1) Spontaneous clonus, (2) Inducible clonus PLUS agitation or diaphoresis, (3) Ocular clonus PLUS agitation or diaphoresis, (4) Tremor PLUS hyperreflexia, or (5) Hypertonia PLUS temperature $>38^\circ\text{C}$ PLUS ocular or inducible clonus.
• Management: Immediately discontinue all serotonergic agents; administer IV fluids; control agitation and hyperthermia with intravenous benzodiazepines; administer the $5\text{-HT}_{2A}$ antagonist Cyproheptadine (12 mg initial oral loading dose, followed by 2 mg every 2 hours until response).

4. Multi-Pathway Hemorrhagic Synergy

Combining anticoagulants (DOACs, Warfarin) with antiplatelet agents (Aspirin, Clopidogrel) or NSAIDs significantly multiplies gastrointestinal and intracranial bleeding risk. Furthermore, SSRIs and SNRIs deplete platelet serotonin stores (platelets cannot synthesize serotonin and rely on SERT uptake), impairing platelet aggregation and increasing GI bleeding risk 2- to 3-fold when combined with anticoagulants.